Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review

Clinical, Cosmetic and Investigational Dermatology
Andreas PinterSebastian Zimmer

Abstract

Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1, and 2, then 210 mg every 2 weeks, produced a rapid onset and sustained clinical response. Consistently, >80% of patients achieved PASI-75 and efficacy was maintained for >2 years. The benefits are apparent soon after the start of therapy and are maintained in the long term. Such results, from the reviewed literature, support the findings from 4 'real world' cases in mainstream clinical practice which are reported here. Psoriatic plaques, including on the scalp, nails, soles and palms, were largely resolved, and quality of life improved markedly. Therapeutic success was achieved in patients naïve to biologics (2 cases) and in those responding inadequately to other biologics (2 cases). The high affinity of brodalumab to human IL-17RA blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17C, IL-17E, IL-17F, and IL-17A/F heterodimer, resulting in inhibition of the inflammation and clinical symptoms associated w...Continue Reading

Citations

May 29, 2020·Expert Opinion on Biological Therapy·Paolo Gisondi, Giampiero Girolomoni
Apr 1, 2020·International Journal of Dermatology·Ricardo Ruiz-VillaverdePilar Font-Ugalde
Sep 12, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·M C FargnoliUNKNOWN BRILLIANT Working Group
Mar 23, 2021·Dermatologic Clinics·Dimitrios RigopoulosStamatios Gregoriou

❮ Previous
Next ❯

Software Mentioned

AMAGINE

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here